Athersys, Inc. (ATHX) Shares Sold by Renaissance Technologies LLC
Renaissance Technologies LLC trimmed its holdings in shares of Athersys, Inc. (NASDAQ:ATHX) by 45.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 239,300 shares of the biopharmaceutical company’s stock after selling 200,600 shares during the quarter. Renaissance Technologies LLC owned 0.17% of Athersys worth $503,000 at the end of the most recent reporting period.
Several other large investors have also added to or reduced their stakes in the company. BlackRock Inc. lifted its stake in shares of Athersys by 12.8% in the 3rd quarter. BlackRock Inc. now owns 6,769,421 shares of the biopharmaceutical company’s stock worth $14,217,000 after purchasing an additional 768,755 shares during the period. Alps Advisors Inc. raised its stake in Athersys by 22.5% during the 3rd quarter. Alps Advisors Inc. now owns 245,240 shares of the biopharmaceutical company’s stock worth $515,000 after acquiring an additional 45,024 shares during the period. Millennium Management LLC raised its stake in Athersys by 377.6% during the 2nd quarter. Millennium Management LLC now owns 457,667 shares of the biopharmaceutical company’s stock worth $902,000 after acquiring an additional 361,835 shares during the period. Finally, Schwab Charles Investment Management Inc. raised its stake in Athersys by 50.9% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 250,900 shares of the biopharmaceutical company’s stock worth $495,000 after acquiring an additional 84,600 shares during the period. Institutional investors and hedge funds own 19.56% of the company’s stock.
In related news, insider William Lehmann, Jr. sold 15,000 shares of the firm’s stock in a transaction on Tuesday, December 18th. The shares were sold at an average price of $1.73, for a total value of $25,950.00. Following the completion of the transaction, the insider now directly owns 493,062 shares of the company’s stock, valued at $852,997.26. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 18.60% of the company’s stock.
Athersys (NASDAQ:ATHX) last released its earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. Athersys had a negative net margin of 108.83% and a negative return on equity of 58.74%. The company had revenue of $2.32 million for the quarter, compared to analysts’ expectations of $1.80 million. On average, sell-side analysts expect that Athersys, Inc. will post -0.19 earnings per share for the current year.
A number of research firms have commented on ATHX. Zacks Investment Research cut shares of Athersys from a “buy” rating to a “hold” rating in a research note on Monday. ValuEngine upgraded shares of Athersys from a “hold” rating to a “buy” rating in a research note on Friday, January 25th. Maxim Group set a $8.00 target price on shares of Athersys and gave the stock a “buy” rating in a research note on Wednesday, January 23rd. Finally, BidaskClub upgraded shares of Athersys from a “strong sell” rating to a “sell” rating in a research note on Wednesday, December 12th.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.watchlistnews.com/athersys-inc-athx-shares-sold-by-renaissance-technologies-llc/2801961.html.
Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.
Featured Story: Day Trading
Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.